Clinical Trial Update: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LIB003 with Evolocumab and Alirocumab in high-risk cardiovascular disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Hypercholesterolemia

Drugs mentioned

• Evolocumab (evolocumab)
• LIB003
• alirocumab (alirocumab)

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Hypercholesterolemia, Cardiovascular Diseases | Phase 3 | Status: COMPLETED